Temozolomide in Patients with Advanced Cancer: Phase I and Pharmacokinetic Study

Pharmacotherapy

Volumn 24, Issue 1, 2004, Pages 16-25

  Rudek, Michelle A ^a   Donehower, Ross C ^a   Statkevich, Paul ^b   Batra, Vijay K ^b   Cutler, David L ^b   Baker, Sharyn D ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Alkylating agents; Imidazotetrazine; MTIC; Pharmacokinetics; Phase I; Temozolomide

Indexed keywords

5 (3 METHYLTRIAZENO) 4 IMIDAZOLECARBOXAMIDE; 6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; ALKYLATING AGENT; DRUG METABOLITE; GRANISETRON; ONDANSETRON; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPOGLYCEMIA; LIVER DYSFUNCTION; LYMPHOMA; MALE; NAUSEA; NEUTROPENIA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; SINGLE DRUG DOSE; SOLID TUMOR; THROMBOCYTOPENIA; URINARY EXCRETION; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ALKALINE PHOSPHATASE; ALKYLATING AGENTS; AREA UNDER CURVE; BILIRUBIN; CAPSULES; DACARBAZINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HALF-LIFE; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; THROMBOCYTOPENIA; TISSUE DISTRIBUTION; TREATMENT FAILURE;

EID: 0346727329     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.1.16.34800     Document Type: Article

References (31)

1. Newlands ES, Blackledge GR, Slack JA, et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 1992;65:287-91.
2. O'Reilly SM, Newlands ES, Glaser MG, et al. Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer 1993;29A:940-2.
3. Bleehen NM, Newlands ES, Lee SM, et al. Cancer research campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 1995;13:910-13.
4. Woll PJ, Crowther D, Johnson PW, et al. Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma. Br J Cancer 1995;72:183-4.
5. Dhodapkar M, Rubin J, Reid JM, et al. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. Clin Cancer Res 1997;3:1093-100.
6. Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res 2000;6:2585-97.
7. Gibson NW, Hickman JA, Erickson LC. DNA cross-linking and cytotoxicity in normal and transformed human cells treated in vitro with 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one. Cancer Res 1984;44:1772-5.
8. Hartley JA, Gibson NW, Kohn KW, Mattes WB. DNA sequence selectivity of guanine-N7 alkylation by three antitumor chloroethylating agents. Cancer Res 1986;46:1943-7.
9. Denny BJ, Wheelhouse RT, Stevens MF, Tsang LL, Slack JA. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 1994;33:9045-51.
10. 6-Methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. Br J Cancer 1998;78:1199-202.
11. Liu L, Markowitz S, Gerson SL. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. Cancer Res 1996;56:5375-9.
12. Hammond LA, Eckardt JR, Baker SD, et al. Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. J Clin Oncol 1999;17:2604-13.
13. Brock CS, Newlands ES, Wedge SR, et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 1998;58:4363-7.
14. Khan RB, Raizer JJ, Malkin MG, Bazylewicz KA, Abrey LE. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro-oncol 2002;4:39-43.
15. Denis LJ, Tolcher A, Figueroa JA, et al. Protracted daily administration of temozolomide is feasible: a phase I and pharmacokinetic-pharmacodynamic study [abstr]. Proc Amer Soc Clin Oncol 2000;19:202a.
16. Wurm RE, Roeschel L, Scheffier D, et al. Phase I-II study with continuous dose-escalated 21-day schedule temozolomide in recurrent high-grade glioma [abstr]. Proc Amer Soc Clin Oncol 2000;19:164a.
17. Baker SD, Wirth M, Statkevich P, et al. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res 1999;5:309-17.
18. Reid JM, Stevens DC, Rubin J, Ames MM. Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer. Clin Cancer Res 1997;3:2393-8.
19. Jen JF, Cutler DL, Pai SM, et al. Population pharmacokinetics of temozolomide in cancer patients. Pharm Res 2000;17:1284-9.
20. Division of Cancer Treatment, National Cancer Institute. Guidelines for reporting of adverse drug reactions. Bethesda, MD: National Cancer Institute, 1988.
21. World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva: WHO Offset Publication, 1979.
22. Kim H, Likhari P, Parker D, et al. High-performance liquid chromatographic analysis and stability of anti-tumor agent temozolomide in human plasma. J Pharm Biomed Anal 2001;24:461-8.
23. Gibaldi M, Perrier D, eds. Noncompartmental analysis based on statistical moment theory. In: Pharmacokinetics, 2nd ed. New York: Marcel Dekker, 1982:409-17.
24. D'Argenio DZ, Schumitzky A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed 1979;9:115-34.
25. Gibaldi M, ed. Biopharmaceutics and clinical pharmacokinetics, 4th ed. Philadelphia: Lea and Febiger, 1991:220-1.
26. 6-alkylguanine-DNA alkyl-transferase activity. Br J Cancer 1996;74:1030-6.
27. 6-benzylguanine: a comparative study in vitro. Br J Cancer 1996;73:482-90.
28. 6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. Cancer Res 1991;51:3367-72.
29. Bower M, Newlands ES, Bleehen NM, et al. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 1997;40:484-8.
30. Newlands ES, O'Reilly SM, Glaser MG, et al. The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer 1996;32A:2236-41.
31. Stevens MF, Hickman JA, Langdon SP, et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 1987;47:5846-52.